Primex Pharmaceuticals AG, a Switzerland-based pharmaceutical company, has named Dan Spacie as its new global commercial head, it was reported yesterday.
Dan Spacie joined Primex Pharmaceuticals from Syneos Health, where he was president, Commercial, Europe. Prior to Syneos, he held several leadership roles including managing director at STADA UK affiliates for five years. He has extensive international leadership experience in growing sales and enhancing profitability of generics, branded pharmaceuticals and launching biopharmaceuticals.
In the new role, Spacie is responsible for global Commercialisation, working with both the company's partners and direct field forces across the portfolio and with the launch of OZALIN in the European Union. He will be part of the executive team headed by CEO Alan Knox and is based in Zug, Switzerland.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules